Research
Hormonal
Adiponectin is an adipokine secreted exclusively by adipose tissue that improves insulin sensitivity and fatty acid oxidation, with levels inversely correlated to fat mass, making its reduction in obesity a key factor in metabolic dysfunction.
Adiponectin is a hormone made only by fat cells that helps your body use insulin and burn fatty acids. People with more body fat typically have lower levels of adiponectin, which contributes to insulin resistance. Maintaining a healthy weight helps preserve these beneficial hormone levels.
StrongSupportsHIGH confidence
Adiponectin is secreted exclusively from adipose tissue [23]. There is a strong negative correlation between plasma adiponectin concentration in humans and fat mass... In models of genetic and diet-induced obesity, adiponectin was shown to improve whole-body insulin sensitivity. Another role of adiponectin is to stimulate fatty acid oxidation and glucose uptake in skeletal muscle and adipose tissue...
Why this rating
Well-established in the literature reviewed.
Source
State of the art paper Biochemistry of adipose tissue: an endocrine organ
Marisa Coelho et al. · Archives of Medical Science · 2013
DOI 10.5114/aoms.2013.33181
narrative_reviewCited 1,082×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Adipose tissue functions as an active endocrine organ that secretes adipocytokines (e.g., TNF-α, IL-6, leptin, adiponectin) which regulate whole-body metabolism, insulin sensitivity, and inflammation, rather than serving merely as inert fat storage.Strong
- Obesity induces a state of chronic low-grade inflammation in adipose tissue, primarily driven by macrophage infiltration and the secretion of pro-inflammatory cytokines (TNF-α, IL-6), which directly impairs insulin signaling and contributes to insulin resistance.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →